Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma

被引:29
作者
Wintachai, Preawwalee [1 ,2 ]
Lim, Jing Quan [3 ,4 ]
Techasen, Anchalee [2 ,5 ]
Lert-Itthiporn, Worachart [6 ]
Kongpetch, Sarinya [2 ,7 ]
Loilome, Watcharin [2 ,6 ]
Chindaprasirt, Jarin [2 ,8 ]
Titapun, Attapol [2 ,9 ]
Namwat, Nisana [2 ,6 ]
Khuntikeo, Narong [2 ,9 ]
Jusakul, Apinya [2 ,5 ]
机构
[1] Khon Kaen Univ, Grad Sch, Biomed Sci Program, Khon Kaen 40002, Thailand
[2] Khon Kaen Univ, Cholangiocarcinoma Res Inst, Khon Kaen 40002, Thailand
[3] Natl Canc Ctr, Div Med Oncol, Lymphoma Genom Translat Res Lab, Singapore 169857, Singapore
[4] Duke NUS Med Sch, Singapore 169857, Singapore
[5] Khon Kaen Univ, Fac Associated Med Sci, Ctr Res & Dev Med Diagnost Labs, Khon Kaen 40002, Thailand
[6] Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen 40002, Thailand
[7] Khon Kaen Univ, Fac Med, Dept Pharmacol, Khon Kaen 40002, Thailand
[8] Khon Kaen Univ, Fac Med, Dept Internal Med, Khon Kaen 40002, Thailand
[9] Khon Kaen Univ, Fac Med, Dept Surg, Khon Kaen 40002, Thailand
关键词
bile duct cancer; cell-free DNA; circulating tumor DNA; prognosis; diagnosis; liquid biopsy; sequencing; TUMOR DNA; CANCER; MARKER; BLOOD; INFECTION; PATTERNS; MUTATION; CA19-9; GENOME; PBRM1;
D O I
10.3390/diagnostics11060999
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The analysis of cfDNA has been applied as a liquid biopsy in several malignancies. However, its value in the diagnosis and prognosis of cholangiocarcinoma (CCA) have not been well defined. We aimed to investigate the diagnostic and prognostic values of cfDNA level and tumor-specific mutation in circulating DNA (ctDNA) in CCA. The plasma cfDNA levels from 62 CCA patients, 33 benign biliary disease (BBD) patients and 30 normal controls were quantified by fluorescent assay. Targeted probe-based sequencing of 60 genes was applied for mutation profiling in 10 ctDNA samples and their corresponding treatment-naive tissues. cfDNA levels in CCA were significantly higher than those in BBD and normal controls. We found that cfDNA levels at 0.2175 and 0.3388 ng/mu L significantly discriminated CCA from healthy controls and BBD with 88.7 and 82.3% sensitivity and 96.7 and 57.6% specificity, respectively. cfDNA levels showed superior diagnostic efficacy in detecting CCA compared to CEA and CA19-9. ARID1A (30%), PBRM1 (30%), MTOR (30%), and FGFR3 (30%) mutations were the most common. Using nine frequently mutated genes in the ctDNA samples, the diagnostic accuracy of cfDNA sequencing was 90.8%, with 96.7% average sensitivity and 72.4% specificity. This study supports the use of cfDNA as a diagnosis and prognostic biomarker for CCA.
引用
收藏
页数:19
相关论文
共 62 条
[51]   Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand [J].
Sriamporn, S ;
Pisani, P ;
Pipitgool, V ;
Suwanrungruang, K ;
Kamsa-Ard, S ;
Parkin, DM .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2004, 9 (05) :588-594
[52]   COSMIC: the Catalogue Of Somatic Mutations In Cancer [J].
Tate, John G. ;
Bamford, Sally ;
Jubb, Harry C. ;
Sondka, Zbyslaw ;
Beare, David M. ;
Bindal, Nidhi ;
Boutselakis, Harry ;
Cole, Charlotte G. ;
Creatore, Celestino ;
Dawson, Elisabeth ;
Fish, Peter ;
Harsha, Bhavana ;
Hathaway, Charlie ;
Jupe, Steve C. ;
Kok, Chai Yin ;
Noble, Kate ;
Ponting, Laura ;
Ramshaw, Christopher C. ;
Rye, Claire E. ;
Speedy, Helen E. ;
Stefancsik, Ray ;
Thompson, Sam L. ;
Wang, Shicai ;
Ward, Sari ;
Campbell, Peter J. ;
Forbes, Simon A. .
NUCLEIC ACIDS RESEARCH, 2019, 47 (D1) :D941-D947
[53]   Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration [J].
Thorvaldsdottir, Helga ;
Robinson, James T. ;
Mesirov, Jill P. .
BRIEFINGS IN BIOINFORMATICS, 2013, 14 (02) :178-192
[54]   Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression [J].
Titapun, Attapol ;
Techasen, Anchalee ;
Sa-Ngiamwibool, Prakasit ;
Sithithaworn, Paiboon ;
Luvira, Vor ;
Srisuk, Tharatip ;
Jareanrat, Apiwat ;
Dokduang, Hasaya ;
Loilonne, Watcharin ;
Thinkhamrop, Bandit ;
Khuntikeo, Narong .
INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2020, 13 :1271-1283
[55]   Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Valle, J. W. ;
Borbath, I. ;
Khan, S. A. ;
Huguet, F. ;
Gruenberger, T. ;
Arnold, D. .
ANNALS OF ONCOLOGY, 2016, 27 :v28-v37
[56]   Intraductal biopsies in indeterminate biliary stricture: Evaluation of histopathological criteria in fluoroscopy- vs. cholangioscopy guided technique [J].
Walter, Dirk ;
Peveling-Oberhag, Jan ;
Schulze, Falko ;
Bon, Dimitra ;
Zeuzem, Stefan ;
Friedrich-Rust, Mireen ;
Alberta, Joerg G. .
DIGESTIVE AND LIVER DISEASE, 2016, 48 (07) :765-770
[57]   mTOR Inhibitors in Advanced Biliary Tract Cancers [J].
Wu, Chao-En ;
Chen, Ming-Huang ;
Yeh, Chun-Nan .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (03)
[58]   Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma [J].
Yan, Linlin ;
Chen, Yanhui ;
Zhou, Jiyuan ;
Zhao, Hong ;
Zhang, Henghui ;
Wang, Guiqiang .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 67 :92-97
[59]   Targeting PI3K in cancer: mechanisms and advances in clinical trials [J].
Yang, Jing ;
Nie, Ji ;
Ma, Xuelei ;
Wei, Yuquan ;
Peng, Yong ;
Wei, Xiawei .
MOLECULAR CANCER, 2019, 18 (1)
[60]   Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA [J].
Zemmour, Hai ;
Planer, David ;
Magenheim, Judith ;
Moss, Joshua ;
Neiman, Daniel ;
Gilon, Dan ;
Korach, Amit ;
Glaser, Benjamin ;
Shemer, Ruth ;
Landesberg, Giora ;
Dor, Yuval .
NATURE COMMUNICATIONS, 2018, 9